Amanote Research
Register
Sign In
Ibrutinib Plus Palbociclib Has Efficacy in Mantle Cell Lymphoma
Cancer Discovery
- United States
doi 10.1158/2159-8290.cd-rw2019-016
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
February 8, 2019
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
BTK Inhibitor Ibrutinib in CLL and Mantle Cell Lymphoma
Community Oncology
Obinutuzumab Plus Ibrutinib in Relapse/Refractory Mantle Cell Lymphoma Patients: First Results of the Oasis Phase I Trial
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Novel Chemotherapy-Free Combination Regimen for Ibrutinib-Resistant Mantle Cell Lymphoma
British Journal of Haematology
Hematology
Expanding Horizons in the Treatment of Mantle Cell Lymphoma: Ibrutinib a Novel BTK-targeting Inhibitor
International Journal of Basic & Clinical Pharmacology
Integrated Stress Response and Immune Cell Infiltration in an Ibrutinib-Refractory Mantle Cell Lymphoma Patient Following ONC201 Treatment
British Journal of Haematology
Hematology
Differential Effects of BTK Inhibitors Ibrutinib and Zanubrutinib on NK Cell Effector Function in Patients With Mantle Cell Lymphoma
Haematologica
Hematology
Long-Term Outcomes and Mutation Profiling of Patients With Mantle Cell Lymphoma (MCL) Who Discontinued Ibrutinib
British Journal of Haematology
Hematology
A Case of New-Onset Cardiomyopathy and Ventricular Tachycardia in a Patient Receiving Ibrutinib for Relapsed Mantle Cell Lymphoma
Clinical Case Reports
Medicine
The Efficacy of Ibrutinib in Patients With Relapsed Mantle Cell Lymphoma After First Line Intensive Chemo-Immunotherapy and Asct - A Retrospective Study From the LWP-Ebmt
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
